These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8391325)
1. Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity. Bleasdale JE; Swanson ML Biochim Biophys Acta; 1993 Jun; 1181(3):240-8. PubMed ID: 8391325 [TBL] [Abstract][Full Text] [Related]
2. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Hofmann CA; Edwards CW; Hillman RM; Colca JR Endocrinology; 1992 Feb; 130(2):735-40. PubMed ID: 1733721 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Castle CK; Colca JR; Melchior GW Arterioscler Thromb; 1993 Feb; 13(2):302-9. PubMed ID: 8427865 [TBL] [Abstract][Full Text] [Related]
4. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Weinstock RS; Murray FT; Diani A; Sangani GA; Wachowski MB; Messina JL Pharmacology; 1997 Apr; 54(4):169-78. PubMed ID: 9211562 [TBL] [Abstract][Full Text] [Related]
5. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Saha AK; Kurowski TG; Colca JR; Ruderman NB Am J Physiol; 1994 Jul; 267(1 Pt 1):E95-101. PubMed ID: 8048519 [TBL] [Abstract][Full Text] [Related]
6. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Diani AR; Sawada G; Wyse B; Murray FT; Khan M Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E116-22. PubMed ID: 14532171 [TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Sugiyama Y; Shimura Y; Ikeda H Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715 [TBL] [Abstract][Full Text] [Related]
8. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Tang Y; Osawa H; Onuma H; Nishimiya T; Ochi M; Makino H Diabetes; 1999 Sep; 48(9):1830-5. PubMed ID: 10480615 [TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Ikeda H; Taketomi S; Sugiyama Y; Shimura Y; Sohda T; Meguro K; Fujita T Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):156-62. PubMed ID: 2334455 [TBL] [Abstract][Full Text] [Related]
10. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Morimoto Y; Nishikawa K; Ohashi M Life Sci; 1997; 61(8):795-803. PubMed ID: 9275009 [TBL] [Abstract][Full Text] [Related]
11. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. Kubota N; Terauchi Y; Kubota T; Kumagai H; Itoh S; Satoh H; Yano W; Ogata H; Tokuyama K; Takamoto I; Mineyama T; Ishikawa M; Moroi M; Sugi K; Yamauchi T; Ueki K; Tobe K; Noda T; Nagai R; Kadowaki T J Biol Chem; 2006 Mar; 281(13):8748-55. PubMed ID: 16431926 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth. Towns R; Kostyo JL; Colca JR Endocrinology; 1994 Feb; 134(2):608-13. PubMed ID: 8299559 [TBL] [Abstract][Full Text] [Related]
13. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. Sohda T; Mizuno K; Momose Y; Ikeda H; Fujita T; Meguro K J Med Chem; 1992 Jul; 35(14):2617-26. PubMed ID: 1635060 [TBL] [Abstract][Full Text] [Related]
14. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Kobayashi M; Iwanishi M; Egawa K; Shigeta Y Diabetes; 1992 Apr; 41(4):476-83. PubMed ID: 1318856 [TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419 [TBL] [Abstract][Full Text] [Related]
16. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs. Matsuhisa M; Shi ZQ; Wan C; Lekas M; Rodgers CD; Giacca A; Kawamori R; Vranic M Diabetes; 1997 Feb; 46(2):224-31. PubMed ID: 9000698 [TBL] [Abstract][Full Text] [Related]
17. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Hofmann C; Lorenz K; Colca JR Endocrinology; 1991 Oct; 129(4):1915-25. PubMed ID: 1915075 [TBL] [Abstract][Full Text] [Related]
18. [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. Ikeda H; Sugiyama Y Nihon Yakurigaku Zasshi; 2001 May; 117(5):335-42. PubMed ID: 11411343 [TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Iwanishi M; Kobayashi M Metabolism; 1993 Aug; 42(8):1017-21. PubMed ID: 8345805 [TBL] [Abstract][Full Text] [Related]
20. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes. Hirshman MF; Fagnant PM; Horton ED; King PA; Horton ES Biochem Biophys Res Commun; 1995 Mar; 208(2):835-45. PubMed ID: 7695642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]